心臓バイオマーカーの世界市場レポート 2025年

心臓バイオマーカーの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR14.4％で365億1,000万米ドルに成長します。予測期間の成長は、慢性疾患の負担増、疾患の早期発見重視の高まり、高齢者人口の拡大、新興市場の開拓、バイオマーカーパネルの重視などに起因すると考えられます。予測期間の主な動向には、患者中心のヘルスケアモデル、AIおよび機械学習用途、デジタルヘルス統合、バイオマーカー発見における技術革新、マルチマーカーパネル、心血管医療におけるリキッドバイオプシーなどが含まれます。

心血管障害の有病率の増加は、心臓バイオマーカー市場の成長を促進すると予想されます。心血管疾患には、冠動脈疾患、心不全、脳卒中などの心臓や血管に影響を及ぼす疾患が含まれます。心臓バイオマーカーは、心筋梗塞（心臓発作）、心不全、不整脈などのさまざまな心血管系の問題に反応して血流に放出される物質です。これらのバイオマーカーは、臨床検査を通じて測定することができ、診断や予後に関する重要な知見を提供します。例えば、2024年9月、英国を拠点とする心臓血管研究慈善団体であるBritish Heart Foundationのデータから、英国では約760万人が心臓・循環器系疾患に罹患しており、そのうち約400万人が男性、約360万人が女性であることが明らかになりました。これらの疾患は英国における全死亡の約27％を占め、毎年17万人以上、1日当たり約480人が死亡しており、これは3分に1人が死亡していることに相当します。したがって、心血管障害の有病率の増加が心臓バイオマーカー市場の拡大に拍車をかけています。

ヘルスケア支出の増加は、心臓バイオマーカー市場の成長を促進すると予想されます。ヘルスケア支出には、保健サービス、家族計画、栄養プログラム、緊急保健支援に関連するすべての費用が含まれ、特に健康アウトカムの改善に重点が置かれています。心臓バイオマーカーへの投資は、早期発見を強化し、個別化治療を可能にし、効率的な資源配分を確保することを目的としており、心血管疾患に関連する全体的なコストを低下させる可能性があります。例えば、英国の政府機関であるOffice for National Statisticsの報告によると、2022～2023年にかけての総ヘルスケア支出は名目ベースで5.6％増加しました。また、2022年の伸びは0.9％でした。このように、ヘルスケア支出の増加が心臓バイオマーカー市場の拡大に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の心臓バイオマーカー市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の心臓バイオマーカー市場：成長率分析
• 世界の心臓バイオマーカー市場の実績：規模と成長、2019～2024年
• 世界の心臓バイオマーカー市場の予測：規模と成長、2024～2029年、2034年
• 世界の心臓バイオマーカー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の心臓バイオマーカー市場：バイオマーカーの種類別、実績と予測、2019～2024年、2024～2029年、2034年
• クレアチンキナーゼ（CK-Mb）
• トロポニン
• ミオグロビン
• ナトリウム利尿ペプチド（BNPおよびNT-proBNP）
• 虚血修飾アルブミン（IMA）
• その他
• 世界の心臓バイオマーカー市場：検査部位別、実績と予測、2019～2024年、2024～2029年、2034年
• ポイントオブケア検査
• 臨床検査
• 世界の心臓バイオマーカー市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 心筋梗塞
• うっ血性心不全
• 急性冠症候群（ACS）
• 動脈硬化症
• その他
• 世界の心臓バイオマーカー市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 専門クリニック
• 世界の心臓バイオマーカー市場：クレアチンキナーゼ（CK-Mb）のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• CK-Mb検査キット
• CK-Mb診断パネル
• 世界の心臓バイオマーカー市場：トロポニンのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• トロポニンI検査キット
• トロポニンT検査キット
• トロポニン診断パネル
• 世界の心臓バイオマーカー市場：ミオグロビンのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ミオグロビン検査キット
• ミオグロビン診断パネル
• 世界の心臓バイオマーカー市場：ナトリウム利尿ペプチド（BNPおよびNT-proBNP）のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• BNP検査キット
• NT-ProBNP検査キット
• ナトリウム利尿ペプチド診断パネル
• 世界の心臓バイオマーカー市場：虚血修飾アルブミン（IMA）のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• IMA検査キット
• IMA診断パネル
• 世界の心臓バイオマーカー市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 心臓脂肪酸結合蛋白（HFABP）
• C反応性蛋白（CRP）
• その他の新しいバイオマーカー

第7章 地域別・国別分析

• 世界の心臓バイオマーカー市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の心臓バイオマーカー市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 心臓バイオマーカー市場：競合情勢
• 心臓バイオマーカー市場：企業プロファイル
  • bioMerieux Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bio-Rad Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Siemens AG Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Creative Diagnostics
• Randox Laboratories Ltd.
• Becton Dickinson and Company
• Tosoh Corporation
• Life Diagnostics
• PerkinElmer Inc.
• Quidel Corporation
• ACS Biomarker BV
• LSI Medience Corp.
• BioDot
• Alere Inc.
• Biosensors International Group
• Biosynex SA
• CardioGenics Holdings Inc.
• Danaher Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 心臓バイオマーカー市場2029年：新たな機会を提供する国
• 心臓バイオマーカー市場2029年：新たな機会を提供するセグメント
• 心臓バイオマーカー市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cardiac biomarkers represent substances released by the heart into the bloodstream during periods of injury or stress, aiding in the detection and measurement of various cardiac and vascular conditions.

The primary categories of cardiac biomarkers encompass creatine kinase (CK-MB), troponins, myoglobin, natriuretic peptides (BNP and NT-proBNP), ischemia-modified albumin (IMA), among others. Creatine kinase (CK) is an enzyme present in multiple body tissues, including muscles and the brain, commonly utilized in diagnosing myocardial infarction (MI), commonly known as a heart attack. These biomarkers find application across diverse testing settings such as point-of-care and laboratory-based assessments. They serve multiple diagnostic purposes, including testing for myocardial infarction, congestive heart failure, acute coronary syndrome (ACS), atherosclerosis, among other cardiac conditions. Hospitals and specialized clinics heavily rely on these biomarkers in their diagnostic protocols.

The cardiac biomarkers market research report is one of a series of new reports from The Business Research Company that provides cardiac biomarkers market statistics, including cardiac biomarkers industry global market size, regional shares, competitors with a cardiac biomarkers market share, detailed cardiac biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac biomarkers industry. This cardiac biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cardiac biomarkers market size has grown rapidly in recent years. It will grow from$18.99 billion in 2024 to $21.32 billion in 2025 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to increased healthcare expenditure, FDA approvals and regulatory support, aging population, awareness programs, high sensitivity troponin tests, increasing cardiovascular diseases

The cardiac biomarkers market size is expected to see rapid growth in the next few years. It will grow to $36.51 billion in 2029 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to rising burden of chronic diseases, growing emphasis on early disease detection, expansion of geriatric population, emerging markets development, focus on biomarker panels. Major trends in the forecast period include patient-centric healthcare models, ai and machine learning applications, digital health integration, technological innovations in biomarker discovery, multi-marker panels, liquid biopsy in cardiovascular medicine.

The increasing prevalence of cardiovascular disorders is expected to drive the growth of the cardiac biomarker market. Cardiovascular disorders encompass diseases that affect the heart and blood vessels, including conditions like coronary artery disease, heart failure, and stroke. Cardiac biomarkers are substances released into the bloodstream in response to various cardiovascular issues, such as myocardial infarction (heart attack), heart failure, and arrhythmias. These biomarkers can be measured through laboratory tests, providing critical diagnostic and prognostic insights. For example, in September 2024, data from the British Heart Foundation, a UK-based cardiovascular research charity, revealed that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, with around 4 million men and 3.6 million women living with these conditions. These diseases account for about 27% of all deaths in the UK, resulting in over 170,000 fatalities each year, or roughly 480 deaths per day, which equates to one death every three minutes. Therefore, the growing prevalence of cardiovascular disorders is fueling the expansion of the cardiac biomarker market.

The increase in healthcare expenditures is anticipated to drive the growth of the cardiac biomarker market. Healthcare expenditures encompass all costs related to health services, family planning, nutrition programs, and emergency health assistance, with a specific focus on improving health outcomes. Investment in cardiac biomarkers is aimed at enhancing early detection, enabling personalized treatment, and ensuring efficient resource allocation, which can potentially lower the overall costs associated with cardiovascular diseases. For example, a report from the Office for National Statistics, a UK-based government department, indicated that total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a mere 0.9% growth in 2022. Consequently, the increase in healthcare expenditures is fueling the expansion of the cardiac biomarker market.

Technological advancements are becoming a prominent trend in the cardiac biomarker market. Companies in this sector are increasingly adopting new technologies to maintain their competitive edge. For example, in October 2023, Mindray, a China-based medical devices company, introduced new high-sensitivity cardiac biomarkers, troponin I (hs-cTnI) and NT-proBNP, aimed at improving the diagnosis and management of cardiovascular diseases (CVDs). The hs-cTnI biomarker is crucial for detecting myocardial injury, offering an impressive detection rate and low variability, making it essential for early screening and risk assessment in conditions such as Acute Coronary Syndrome (ACS). On the other hand, NT-proBNP is a well-recognized marker for heart failure, aiding in its detection and management while demonstrating high precision and minimal interference from commonly prescribed heart medications. Together, these biomarkers greatly enhance clinical decision-making in urgent cardiovascular care.

Prominent companies in the cardiac biomarker market are dedicated to developing innovative assays to expand their product portfolios, aiming to enhance patient outcomes and address unmet medical needs. These innovative biomarker assays contribute to advancements in cardiac diagnostics, improving accuracy and diagnostic capabilities. For instance, in October 2023, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. launched two new cardiac biomarkers, high-sensitivity troponin I (hs-cTnI) and NT-proBNP. These additions augment Mindray's varied portfolio of cardiac biomarkers, bolstering capabilities in diagnosing and managing cardiovascular diseases (CVDs).

In December 2023, Mindray, a medical devices company based in China, acquired DiaSys Diagnostic Systems GmbH for an undisclosed amount. This acquisition aims to strengthen Mindray's global competitiveness in in vitro diagnostics by integrating DiaSys' capabilities and broadening its international presence. DiaSys Diagnostic Systems GmbH, located in Germany, specializes in the field of in vitro diagnostics.

Major companies operating in the cardiac biomarkers market include bioMerieux Inc., Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Siemens AG, Thermo Fisher Scientific Inc., Creative Diagnostics, Randox Laboratories Ltd., Becton Dickinson and Company, Tosoh Corporation, Life Diagnostics, PerkinElmer Inc., Quidel Corporation, ACS Biomarker BV, LSI Medience Corp., BioDot, Alere Inc., Biosensors International Group, Biosynex SA, CardioGenics Holdings Inc., Danaher Corporation, Cortez Diagnostics Inc., DIALAB GmbH, Eurolyser Diagnostica GmbH, Grifols SA, Hologic Inc., InfraRedx Inc., Labcorp Corp., Lepu Medical Technology, Myriad Genetics, Nanosphere Inc., Biora Therapeutics Inc., Quest Diagnostics

North America was the largest region in the cardiac biomarkers market in 2024. The regions covered in the cardiac biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cardiac biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The cardiac biomarkers market consists of sales of assays and reagents, point-of-care testing (POCT) devices, instruments, and software solutions. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cardiac Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cardiac biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cardiac biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cardiac biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Biomarkers Type: Creatine Kinase (CK-Mb); Troponins; Myoglobin; Natriuretic Peptides (BNP And NT-proBNP); Ischemia Modified Albumin (IMA); Other Biomarker Types
• 2) By Location Of Testing: Point Of Care Testing; Laboratory Testing
• 3) By Application: Myocardial Infarction; Congestive Heart Failure; Acute Coronary Syndrome (ACS); Atherosclerosis; Other Applications
• 4) By End User: Hospitals; Specialty Clinics
• Subsegments:
• 1) By Creatine Kinase (CK-Mb): CK-Mb Test Kits; CK-Mb Diagnostic Panels
• 2) By Troponins: Troponin I Test Kits; Troponin T Test Kits; Troponin Diagnostic Panels
• 3) By Myoglobin: Myoglobin Test Kits; Myoglobin Diagnostic Panels
• 4) By Natriuretic Peptides (BNP And NT-proBNP): BNP Test Kits; NT-ProBNP Test Kits; Natriuretic Peptides Diagnostic Panels
• 5) By Ischemia Modified Albumin (IMA): IMA Test Kits; IMA Diagnostic Panels
• 6) By Other Biomarker Types: Heart Fatty Acid Binding Protein (HFABP); C-Reactive Protein (CRP); Other Emerging Biomarkers
• Companies Mentioned: bioMerieux Inc.; Bio-Rad Laboratories; F. Hoffmann-La Roche AG; Siemens AG; Thermo Fisher Scientific Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cardiac Biomarkers Market Characteristics

3. Cardiac Biomarkers Market Trends And Strategies

4. Cardiac Biomarkers Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Cardiac Biomarkers Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cardiac Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cardiac Biomarkers Market Growth Rate Analysis
• 5.4. Global Cardiac Biomarkers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cardiac Biomarkers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cardiac Biomarkers Total Addressable Market (TAM)

6. Cardiac Biomarkers Market Segmentation

• 6.1. Global Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Creatine Kinase (CK-Mb)
• Troponins
• Myoglobin
• Natriuretic Peptides (BNP And NT-proBNP)
• Ischemia Modified Albumin (IMA)
• Other Biomarker Types
• 6.2. Global Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Point Of Care Testing
• Laboratory Testing
• 6.3. Global Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome (ACS)
• Atherosclerosis
• Other Applications
• 6.4. Global Cardiac Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• 6.5. Global Cardiac Biomarkers Market, Sub-Segmentation Of Creatine Kinase (CK-Mb), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CK-Mb Test Kits
• CK-Mb Diagnostic Panels
• 6.6. Global Cardiac Biomarkers Market, Sub-Segmentation Of Troponins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Troponin I Test Kits
• Troponin T Test Kits
• Troponin Diagnostic Panels
• 6.7. Global Cardiac Biomarkers Market, Sub-Segmentation Of Myoglobin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Myoglobin Test Kits
• Myoglobin Diagnostic Panels
• 6.8. Global Cardiac Biomarkers Market, Sub-Segmentation Of Natriuretic Peptides (BNP And NT-proBNP), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• BNP Test Kits
• NT-ProBNP Test Kits
• Natriuretic Peptides Diagnostic Panels
• 6.9. Global Cardiac Biomarkers Market, Sub-Segmentation Of Ischemia Modified Albumin (IMA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• IMA Test Kits
• IMA Diagnostic Panels
• 6.10. Global Cardiac Biomarkers Market, Sub-Segmentation Of Other Biomarker Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Heart Fatty Acid Binding Protein (HFABP)
• C-Reactive Protein (CRP)
• Other Emerging Biomarkers

7. Cardiac Biomarkers Market Regional And Country Analysis

• 7.1. Global Cardiac Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cardiac Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cardiac Biomarkers Market

• 8.1. Asia-Pacific Cardiac Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cardiac Biomarkers Market

• 9.1. China Cardiac Biomarkers Market Overview
• 9.2. China Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cardiac Biomarkers Market

• 10.1. India Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cardiac Biomarkers Market

• 11.1. Japan Cardiac Biomarkers Market Overview
• 11.2. Japan Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cardiac Biomarkers Market

• 12.1. Australia Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cardiac Biomarkers Market

• 13.1. Indonesia Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cardiac Biomarkers Market

• 14.1. South Korea Cardiac Biomarkers Market Overview
• 14.2. South Korea Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cardiac Biomarkers Market

• 15.1. Western Europe Cardiac Biomarkers Market Overview
• 15.2. Western Europe Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cardiac Biomarkers Market

• 16.1. UK Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cardiac Biomarkers Market

• 17.1. Germany Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cardiac Biomarkers Market

• 18.1. France Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cardiac Biomarkers Market

• 19.1. Italy Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cardiac Biomarkers Market

• 20.1. Spain Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cardiac Biomarkers Market

• 21.1. Eastern Europe Cardiac Biomarkers Market Overview
• 21.2. Eastern Europe Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cardiac Biomarkers Market

• 22.1. Russia Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cardiac Biomarkers Market

• 23.1. North America Cardiac Biomarkers Market Overview
• 23.2. North America Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cardiac Biomarkers Market

• 24.1. USA Cardiac Biomarkers Market Overview
• 24.2. USA Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cardiac Biomarkers Market

• 25.1. Canada Cardiac Biomarkers Market Overview
• 25.2. Canada Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cardiac Biomarkers Market

• 26.1. South America Cardiac Biomarkers Market Overview
• 26.2. South America Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cardiac Biomarkers Market

• 27.1. Brazil Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cardiac Biomarkers Market

• 28.1. Middle East Cardiac Biomarkers Market Overview
• 28.2. Middle East Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cardiac Biomarkers Market

• 29.1. Africa Cardiac Biomarkers Market Overview
• 29.2. Africa Cardiac Biomarkers Market, Segmentation By Biomarkers Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cardiac Biomarkers Market, Segmentation By Location Of Testing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cardiac Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cardiac Biomarkers Market Competitive Landscape And Company Profiles

• 30.1. Cardiac Biomarkers Market Competitive Landscape
• 30.2. Cardiac Biomarkers Market Company Profiles
  • 30.2.1. bioMerieux Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bio-Rad Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Siemens AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Cardiac Biomarkers Market Other Major And Innovative Companies

• 31.1. Creative Diagnostics
• 31.2. Randox Laboratories Ltd.
• 31.3. Becton Dickinson and Company
• 31.4. Tosoh Corporation
• 31.5. Life Diagnostics
• 31.6. PerkinElmer Inc.
• 31.7. Quidel Corporation
• 31.8. ACS Biomarker BV
• 31.9. LSI Medience Corp.
• 31.10. BioDot
• 31.11. Alere Inc.
• 31.12. Biosensors International Group
• 31.13. Biosynex SA
• 31.14. CardioGenics Holdings Inc.
• 31.15. Danaher Corporation

32. Global Cardiac Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cardiac Biomarkers Market

34. Recent Developments In The Cardiac Biomarkers Market

35. Cardiac Biomarkers Market High Potential Countries, Segments and Strategies

• 35.1 Cardiac Biomarkers Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cardiac Biomarkers Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cardiac Biomarkers Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer